SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...

Hormone therapy is commonly combined with radiation therapy for prostate cancer, but patients are often unsure how long it should be continued and why. A new study published in JAMA Oncology from ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

ADT reduces testosterone, crucial for prostate cancer cell growth, but causes side effects impacting quality of life. Cardiovascular risks, insulin resistance, and bone density loss are significant ...

The ArteraAI Prostate Test uses AI to analyze biopsy images, predicting hormone therapy benefits for prostate cancer patients. Approved in the US and UK, the test aids early diagnostic decisions, ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...